Comparative Study about the Therapeutic Effect between Single and Five-Day Administration of Gammaglobulin in Kawasaki Disease.
10.4070/kcj.1994.24.1.77
- Author:
Seong Yeob MOON
;
Nam Su KIM
;
Ha Baik LEE
;
Hahang LEE
- Publication Type:Comparative Study ; Original Article
- Keywords:
Kawaski disease;
Single gammaglobulin therapy
- MeSH:
Blood Platelets;
Coronary Aneurysm;
Dilatation;
Echocardiography;
Female;
Follow-Up Studies;
Humans;
Infusions, Intravenous;
Male;
Mucocutaneous Lymph Node Syndrome*;
Pathology;
Platelet Count;
Urinary Bladder
- From:Korean Circulation Journal
1994;24(1):77-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This study was designed to evaluate the therapeutic effect between single(A group) and five-day(B group) administration of IV gammaglobulin in the patients with Kawasaki disease from June 1987 to September 1993, who were admitted to the Department of Pediatrcs, Hanyang University College of Medicine. The clinical and echocardiographic results were as follows. 1) Of 90 cases, 40 cases belong to A group, and 50 cases to B group. The ratio of male to female was 2.60 : 1, and 85% of A group and 76% of B group was under the age of 3 years. 2) In 90% of A group and 88% of B group, peak level of platelet count was above 400,000.mm3, and as a whole peak level of platelet in 88.9% above 400,000/mm3. 3) Complications in S group were hepatitis(22.5%), coronary arterial involvement(12.5%), and gall bladder hydrops(7.5%), and in B group hepatitis(26%), gall bladder hydrops(18%), coronary arterial involvement(12%), pericardial effusion(4%), and meningitis(2%). 4) All 5 cases with mild coronary arterial dilatation in a group had improved in follow up echocardiography after 6 months. And in B group, 5 of 6 cases with coronary arterial involvement had improved, but coronary pathology in one case with large coronary aneurysm sustained after 2 years. In conclusion, we could not find the significant difference in reduction of the duration of illness or the coronary arterial disease between two groups, but we recommend single intravenous infusion of gammaglobulin as soon as possible to prevent severe coronary arterial disease.
